Laboratory-made 1960s compound; licensed medicine in much of the world, neither approved drug nor lawful supplement in the United States. Likely restores flexibility to stiffened cell membranes, so effects are larger in impaired systems. Solid for involuntary jerking in rare epilepsy and childhood breathing spells; contested for declining memory; unsupported when thinking is intact. Reduced blood clotting deserves most attention. (Full Review)

Protocol

Standard cognitive-support regimen

2,400 mg per day

Upper conventional dose 4,800 mg per day; studied range 1,200-4,800 mg per day

Single versus split dosing

Two or three divided doses

Morning and midday preferred, final dose by mid-afternoon; split dosing is the standard in every clinical protocol

Age-related dose adjustment

Set by creatinine clearance

Roughly two-thirds of standard at 50-79 mL/min, one-third at 30-49, one-sixth once daily at 20-29; 800-1,200 mg per day is the conservative start at the older end

Time to effect

Breath-holding spells in children

1-3 months

Consistent, large benefit at one, two and three months in the pooled trials

Age-related cognitive decline

6-12 weeks

Global-impression endpoints assessed at 6-12 weeks; realistic assessment window 8-12 weeks

Reading in developmental dyslexia

12 weeks

Evident at 12 weeks, sustained to 36 weeks; steady state in about three days

Benefits

High: Reduction of cortical myoclonus severity; reduction of breath-holding spells in children

Medium: Global clinical improvement in age-related cognitive decline; cognitive protection during cardiac surgery; improved blood rheology and microcirculation

Low: Written-language recovery in post-stroke aphasia; reduction in vertigo attack frequency; reduction of tardive dyskinesia symptoms; reading improvement in developmental dyslexia; reduction in depression and anxiety scores

Speculative: Cognitive enhancement in cognitively intact adults; mitochondrial and neuroplastic support in brain ageing

Contraindications

Hypersensitivity to piracetam or any pyrrolidone derivative (includes levetiracetam)

Cerebral haemorrhage

Huntington's disease

End-stage kidney disease (creatinine clearance below 20 mL/min or estimated glomerular filtration rate below 15 mL/min/1.73 m²)

Pregnancy and breastfeeding

Within seven days of planned surgery

Active bleeding disorder or documented platelet dysfunction

Key Interactions

Vitamin K antagonists (warfarin, acenocoumarol, phenprocoumon)

Direct oral anticoagulants and antiplatelet agents (apixaban, rivaroxaban, dabigatran, clopidogrel, aspirin)

Thyroid hormone preparations (levothyroxine, liothyronine, desiccated thyroid extract)

Probenecid

Over-the-counter medications (ibuprofen, naproxen, dimenhydrinate, meclizine)

Supplement interactions with additive antiplatelet effect (high-dose fish oil, vitamin E above 400 IU per day, Ginkgo biloba, garlic, curcumin)

Choline sources (alpha-glycerylphosphorylcholine, citicoline, choline bitartrate)

Other racetams and cholinergic drugs (aniracetam, oxiracetam, phenylpiracetam, donepezil, galantamine)

Alcohol (no pharmacokinetic interaction)

Creatinine clearance 20-79 mL/min (dose reduction required), established psychotic disorders, epilepsy (abrupt discontinuation avoided)

Risk & Side Effects

High: Motor restlessness and hyperkinesia; nervousness, agitation and sleep disturbance; weight gain

Medium: Increased bleeding tendency; accumulation in impaired kidney function; gastrointestinal effects; depressed mood

Low: Withdrawal-precipitated myoclonic seizures; aggravation of psychosis and agitation in psychiatric illness; hypersensitivity reactions; ataxia, balance impairment and asthenia; headache; increased early mortality in acute ischaemic stroke

Speculative: Unknown consequences of multi-decade use in healthy people; contaminant and dose exposure from adulterated supplements

Monitoring

Marker	Target	Why
Estimated glomerular filtration rate (eGFR)	≥ 90 mL/min/1.73 m²	Sets the dose; piracetam is cleared entirely by the kidneys
Cystatin C	0.60-0.90 mg/L	Confirms kidney function independently of muscle mass
Platelet count	175-300 × 10⁹/L	Baseline for the antiplatelet effect
Fibrinogen	200-300 mg/dL	Identifies who has scope for haemorheological benefit and tracks the effect
Prothrombin time / international normalized ratio (INR)	INR 0.9-1.1	Detects a pre-existing clotting deficit before adding an antiplatelet agent
Thyroid-stimulating hormone (TSH) with free T4 and free T3	TSH 0.5-2.0 mIU/L; free T4 and free T3 in the upper half of the reference range	Baseline for the documented thyroid-hormone interaction
Homocysteine	6-8 µmol/L	Excludes a treatable driver of cognitive decline before attributing change to piracetam
Body weight and waist circumference	Stable within 1 kg of baseline	Weight gain is among the most commonly reported adverse effects
Objective cognitive battery	Individual baseline; a change exceeding the test's reliable change index	The only way to distinguish a real effect from expectancy

Cadence: Full panel before the first dose; safety panel at 4-8 weeks after the target dose is reached; cognitive testing at 12 weeks; every 6-12 months beyond the first year, plus a check after any dose increase or any new antiplatelet or anticoagulant medication. Body weight weekly.

Qualitative Assessment

Sleep quality and latency: time to fall asleep, night waking, morning refreshment
Cognitive clarity and word-finding: recorded as a daily or weekly rating
Energy and daytime alertness
Mood and irritability
Motor restlessness: fidgeting, inability to sit still, involuntary movement
Bruising and bleeding: unexplained bruises, gum bleeding, prolonged bleeding from minor cuts, heavier menstrual bleeding
Headache pattern: onset, timing relative to dosing, response to a choline source

Piracetam for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment